Safirstein Law LLC Announces That A Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP)

A class action lawsuit has been filed against Medpace Holdings, Inc. on behalf of shareholders for alleged securities fraud. The lawsuit was triggered after Medpace reported a book-to-bill ratio of 1.04 on February 9, 2026, significantly below company guidance, causing the stock to plunge 15.9% to $446.05 per share. The class period covers April 22, 2025 through February 9, 2026.

06/08/2026, 2:00 PM • GlobeNewswire

MEDP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Medpace Holdings, with a June 8, 2026 deadline for lead plaintiff claims. The lawsuit alleges Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Additional class actions are mentioned for Veritone, Inc. and Babcock & Wilcox Enterprises, Inc.

06/07/2026, 5:55 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

06/05/2026, 12:00 PM • GlobeNewswire

ROSEN, A LEADING LAW FIRM, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VERI

Rosen Law Firm is urging investors who purchased Veritone, Inc. securities between October 14, 2025 and April 14, 2026 to join a class action lawsuit before the July 20, 2026 lead plaintiff deadline. The lawsuit alleges that Veritone made false statements about its financial performance, inaccurately recorded revenue and costs, overstated assets, and maintained deficient internal controls, leading to required financial statement restatements.

06/04/2026, 8:46 PM • GlobeNewswire

MEDPACE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP

Rosen Law Firm is notifying investors in Medpace Holdings, Upstart Holdings, and Babcock & Wilcox Enterprises of securities class action lawsuits. The firm alleges that Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Investors with losses exceeding $100,000 are encouraged to secure counsel before the June 8, 2026 deadline to potentially serve as lead plaintiffs.

06/04/2026, 7:18 PM • GlobeNewswire

Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its business performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations, causing the stock to fall 15.9% on February 10, 2026. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

06/02/2026, 12:59 PM • GlobeNewswire

MEDPACE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP

Rosen Law Firm announces a securities class action lawsuit against Medpace Holdings, Inc. for allegedly making false statements about backlog cancellation rates and providing misleading growth projections. Investors who purchased MEDP stock between April 22, 2025 and February 9, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is June 8, 2026.

06/01/2026, 7:06 PM • GlobeNewswire

MEDPACE DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP

A securities class action lawsuit has been filed against Medpace Holdings, Inc. alleging that defendants made false and misleading statements regarding the company's backlog cancellation rates. The lawsuit claims defendants misrepresented cancellation rates as 'well behaved' and provided overly positive growth expectations that could not be sustained. Investors with losses exceeding $100,000 are encouraged to join the class action before the June 8, 2026 lead plaintiff deadline.

05/29/2026, 5:19 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VERI

Rosen Law Firm has filed class action lawsuits against Veritone, Inc., Medpace Holdings, Inc., and Stellantis N.V. on behalf of investors who suffered losses. Veritone is accused of inaccurately recording revenue and costs, overstating financial metrics, and maintaining deficient internal controls, leading to required financial restatements. Investors who purchased securities during specified class periods may be eligible for compensation.

05/26/2026, 7:04 PM • GlobeNewswire

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP

Rosen Law Firm is soliciting investors who suffered losses in Medpace Holdings, Stellantis N.V., and Blaize Holdings to join securities class action lawsuits. The Medpace case alleges the company made false statements about backlog cancellation rates and provided misleading growth projections. The lead plaintiff deadline for Medpace is June 8, 2026.

05/26/2026, 5:54 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the company's book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

05/22/2026, 12:00 PM • GlobeNewswire

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP

Rosen Law Firm is reminding investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 of the June 8, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, providing overly positive growth expectations that could not be sustained.

05/20/2026, 6:00 PM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP

Rosen Law Firm is notifying investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 about a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, claiming they were 'well behaved' while concealing material adverse facts. Investors must move the court by June 8, 2026 to serve as lead plaintiff.

05/18/2026, 8:48 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC

Rosen Law Firm is notifying investors about ongoing securities class action lawsuits against Regencell Bioscience Holdings Limited, Medpace Holdings, Inc., and Gossamer Bio, Inc. The firm is seeking lead plaintiffs with a June 23, 2026 deadline. Investors who purchased securities during specified class periods may be eligible for compensation through contingency fee arrangements.

05/18/2026, 8:12 PM • GlobeNewswire

Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its financial performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations. The stock fell 15.9% on February 10, 2026, following the disclosure. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

05/15/2026, 1:40 PM • GlobeNewswire